COVID-19 and Atrial Fibrillation in Older Patients: Does Oral Anticoagulant Therapy Provide a Survival Benefit?-An Insight from the GeroCovid Registry.
Stefano FumagalliCaterina TrevisanSusanna Del SignoreGiulia PelagalliStefano VolpatoPietro GareriEnrico MosselloAlba MalaraFabio MonzaniAlessandra CoinGiuseppe BellelliGianluca ZiaRaffaele Antonelli Incalzinull nullPublished in: Thrombosis and haemostasis (2021)
AF is a prevalent and severe condition in older COVID-19 patients. Advanced age, dependency, and relevant clinical manifestations of disease characterized a worse prognosis. Preadmission and in-hospital anticoagulant therapies were positively associated with survival.
Keyphrases
- atrial fibrillation
- sars cov
- catheter ablation
- oral anticoagulants
- left atrial
- left atrial appendage
- direct oral anticoagulants
- coronavirus disease
- heart failure
- venous thromboembolism
- free survival
- percutaneous coronary intervention
- healthcare
- physical activity
- community dwelling
- respiratory syndrome coronavirus
- acute care
- drug induced
- mesenchymal stem cells
- bone marrow
- acute coronary syndrome